Tumormarkører ved epitelial ovariecancer

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

Tumormarkører ved epitelial ovariecancer. / Sparholt, Morten H; Høgdall, Estrid; Høgdall, Claus K; Sparholt, Morten H; Høgdall, Estrid; Høgdall, Claus K.

In: Ugeskrift for læger, Vol. 171, No. 48, 23.11.2009, p. 3505-9.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Sparholt, MH, Høgdall, E, Høgdall, CK, Sparholt, MH, Høgdall, E & Høgdall, CK 2009, 'Tumormarkører ved epitelial ovariecancer', Ugeskrift for læger, vol. 171, no. 48, pp. 3505-9.

APA

Sparholt, M. H., Høgdall, E., Høgdall, C. K., Sparholt, M. H., Høgdall, E., & Høgdall, C. K. (2009). Tumormarkører ved epitelial ovariecancer. Ugeskrift for læger, 171(48), 3505-9.

Vancouver

Sparholt MH, Høgdall E, Høgdall CK, Sparholt MH, Høgdall E, Høgdall CK. Tumormarkører ved epitelial ovariecancer. Ugeskrift for læger. 2009 Nov 23;171(48):3505-9.

Author

Sparholt, Morten H ; Høgdall, Estrid ; Høgdall, Claus K ; Sparholt, Morten H ; Høgdall, Estrid ; Høgdall, Claus K. / Tumormarkører ved epitelial ovariecancer. In: Ugeskrift for læger. 2009 ; Vol. 171, No. 48. pp. 3505-9.

Bibtex

@article{c8183fe068a111df928f000ea68e967b,
title = "Tumormark{\o}rer ved epitelial ovariecancer",
abstract = "In October 2007, the Danish government and regions made an agreement comprising acute treatment of ovarian cancer (OC) patients. The acute OC-package includes the tumour marker cancer antigen 125 (CA125) as an essential factor. This marker is yet not optimal due to too low sensitivity/specificity. There is therefore a need for new or supplementary markers to improve the treatment. As the agreement will be influencing all diagnostic procedures, there is, furthermore, a need for information about OC and tumor markers. In this article we review the literature and illustrate future challenges and opportunities in OC marker diagnostics. Udgivelsesdato: 2009-Nov-23",
author = "Sparholt, {Morten H} and Estrid H{\o}gdall and H{\o}gdall, {Claus K} and Sparholt, {Morten H} and Estrid H{\o}gdall and H{\o}gdall, {Claus K}",
note = "Keywords: CA-125 Antigen; Chemotherapy, Adjuvant; Female; Genetic Predisposition to Disease; Humans; Individualized Medicine; Mass Screening; Ovarian Neoplasms; Sensitivity and Specificity; Tumor Markers, Biological",
year = "2009",
month = nov,
day = "23",
language = "Dansk",
volume = "171",
pages = "3505--9",
journal = "Ugeskrift for Laeger",
issn = "0041-5782",
publisher = "Almindelige Danske Laegeforening",
number = "48",

}

RIS

TY - JOUR

T1 - Tumormarkører ved epitelial ovariecancer

AU - Sparholt, Morten H

AU - Høgdall, Estrid

AU - Høgdall, Claus K

AU - Sparholt, Morten H

AU - Høgdall, Estrid

AU - Høgdall, Claus K

N1 - Keywords: CA-125 Antigen; Chemotherapy, Adjuvant; Female; Genetic Predisposition to Disease; Humans; Individualized Medicine; Mass Screening; Ovarian Neoplasms; Sensitivity and Specificity; Tumor Markers, Biological

PY - 2009/11/23

Y1 - 2009/11/23

N2 - In October 2007, the Danish government and regions made an agreement comprising acute treatment of ovarian cancer (OC) patients. The acute OC-package includes the tumour marker cancer antigen 125 (CA125) as an essential factor. This marker is yet not optimal due to too low sensitivity/specificity. There is therefore a need for new or supplementary markers to improve the treatment. As the agreement will be influencing all diagnostic procedures, there is, furthermore, a need for information about OC and tumor markers. In this article we review the literature and illustrate future challenges and opportunities in OC marker diagnostics. Udgivelsesdato: 2009-Nov-23

AB - In October 2007, the Danish government and regions made an agreement comprising acute treatment of ovarian cancer (OC) patients. The acute OC-package includes the tumour marker cancer antigen 125 (CA125) as an essential factor. This marker is yet not optimal due to too low sensitivity/specificity. There is therefore a need for new or supplementary markers to improve the treatment. As the agreement will be influencing all diagnostic procedures, there is, furthermore, a need for information about OC and tumor markers. In this article we review the literature and illustrate future challenges and opportunities in OC marker diagnostics. Udgivelsesdato: 2009-Nov-23

M3 - Tidsskriftartikel

VL - 171

SP - 3505

EP - 3509

JO - Ugeskrift for Laeger

JF - Ugeskrift for Laeger

SN - 0041-5782

IS - 48

ER -

ID: 19977463